Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/03 – EX-99.13(B)

On: Wednesday, 6/30/04, at 2:00pm ET · For: 12/31/03 · Accession #: 897069-4-1263 · File #: 1-12033

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/30/04  Nymox Pharmaceutical Corp         20-F       12/31/03    7:1.1M                                   Foley & Lardner/FA

Annual Report of a Foreign Private Issuer — Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report                                       HTML    928K 
 3: EX-99.11    Code of Conduct                                     HTML    165K 
 4: EX-99.12(A)  Miscellaneous Exhibit                              HTML     11K 
 5: EX-99.12(B)  Miscellaneous Exhibit                              HTML     11K 
 6: EX-99.13(A)  Miscellaneous Exhibit                              HTML      6K 
 7: EX-99.13(B)  Miscellaneous Exhibit                              HTML      6K 
 2: EX-99.8     List of Subsidiaries                                HTML      4K

EX-99.13(B) — Miscellaneous Exhibit

This exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Exhibit 13(b)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Roy Wolvin, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report on Form 20-F for the year ended December 31, 2003 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations on Nymox Pharmaceutical Corporation.

Date: June 30, 2004

/s/ Roy Wolvin
Roy Wolvin
Chief Financial Officer
Nymox Pharmaceutical Corporation

Dates Referenced Herein and Documents Incorporated by Reference

This ‘20-F’ Filing	Date	Other Filings

Filed on:	6/30/04	6-K
For Period End:	12/31/03	6-K
		List all Filings

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/02/23  Nymox Pharmaceutical Corp.        20-F       12/31/22  105:5.5M                                   Pubco Reporting … Inc/FA
 3/30/22  Nymox Pharmaceutical Corp.        20-F       12/31/21  106:6M                                     Pubco Reporting … Inc/FA
 3/29/21  Nymox Pharmaceutical Corp.        20-F       12/31/20  103:4.4M                                   Pubco Reporting … Inc/FA

↑Top

Filing Submission 0000897069-04-001263 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)